Sensei Biotherapeutics (NASDAQ:SNSE) Major Shareholder Millennium Management Llc Buys 6,175 Shares

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) major shareholder Millennium Management Llc bought 6,175 shares of the stock in a transaction dated Wednesday, April 1st. The stock was purchased at an average price of $34.49 per share, with a total value of $212,975.75. Following the purchase, the insider owned 147,731 shares in the company, valued at $5,095,242.19. This trade represents a 4.36% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Millennium Management Llc also recently made the following trade(s):

• On Thursday, March 26th, Millennium Management Llc sold 1,857 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $28.12, for a total value of $52,218.84.
• On Friday, March 27th, Millennium Management Llc sold 505 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $26.81, for a total value of $13,539.05.
• On Monday, March 30th, Millennium Management Llc sold 888 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $26.61, for a total value of $23,629.68.
• On Monday, March 30th, Millennium Management Llc bought 9,533 shares of Sensei Biotherapeutics stock. The stock was purchased at an average price of $25.86 per share, with a total value of $246,523.38.
• On Friday, March 27th, Millennium Management Llc acquired 15,321 shares of Sensei Biotherapeutics stock. The shares were bought at an average price of $26.61 per share, with a total value of $407,691.81.
• On Thursday, March 26th, Millennium Management Llc acquired 5,731 shares of Sensei Biotherapeutics stock. The shares were bought at an average price of $28.62 per share, with a total value of $164,021.22.
• On Tuesday, March 31st, Millennium Management Llc sold 1,591 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $25.49, for a total value of $40,554.59.
• On Wednesday, April 1st, Millennium Management Llc sold 1,150 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $31.65, for a total value of $36,397.50.
• On Tuesday, March 31st, Millennium Management Llc acquired 6,005 shares of Sensei Biotherapeutics stock. The shares were bought at an average price of $28.16 per share, with a total value of $169,100.80.
• On Thursday, April 2nd, Millennium Management Llc sold 7,666 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $32.12, for a total value of $246,231.92.

Sensei Biotherapeutics Trading Up 3.1%

NASDAQ:SNSE traded up $0.61 during trading hours on Friday, reaching $20.43. 40,084 shares of the company traded hands, compared to its average volume of 223,112. The business’s 50-day moving average price is $29.11 and its two-hundred day moving average price is $17.85. The stock has a market capitalization of $27.40 million, a P/E ratio of -1.23 and a beta of -0.18. Sensei Biotherapeutics, Inc. has a 1 year low of $5.25 and a 1 year high of $36.76.

Sensei Biotherapeutics (NASDAQ:SNSE) last announced its quarterly earnings data on Friday, May 15th. The company reported ($131.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($130.83). As a group, equities analysts anticipate that Sensei Biotherapeutics, Inc. will post -2.77 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Sensei Biotherapeutics stock. Renaissance Technologies LLC lifted its holdings in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 178.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 32,041 shares of the company’s stock after purchasing an additional 20,525 shares during the quarter. Renaissance Technologies LLC owned 2.39% of Sensei Biotherapeutics worth $1,010,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 10.50% of the company’s stock.

Sensei Biotherapeutics News Summary

Here are the key news stories impacting Sensei Biotherapeutics this week:

• Positive Sentiment: Sensei Biotherapeutics reported first-quarter 2026 results and said the quarter was “transformational,” highlighting the acquisition of Faeth Therapeutics and a concurrent $200 million private placement backed by leading life sciences investors, which may strengthen the balance sheet and support the company’s strategy. Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
• Neutral Sentiment: The company also disclosed that major shareholder Millennium Management made several purchases in late March and early April, which can signal insider confidence, although the filing also showed some offsetting sales in the same period. SEC insider filing
• Negative Sentiment: The earnings release showed a very large quarterly loss, with reported EPS of ($131.45) versus expectations of ($0.62), underscoring continued financial volatility and likely limiting enthusiasm for the stock. Quarterly earnings press release

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Leerink Partners assumed coverage on Sensei Biotherapeutics in a research note on Monday, April 20th. They set an “outperform” rating and a $50.00 price objective for the company. Zacks Research upgraded Sensei Biotherapeutics to a “hold” rating in a research note on Tuesday, April 21st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research note on Friday, April 24th. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $40.00.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.